We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
RNA therapeutics firm Chimeron Bio has collaborated with George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID) to develop a Covid-19 vaccine candidate.